Grossi Federico 4
4 · Apellis Pharmaceuticals, Inc. · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Grossi Federico
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-03-15$4.31/sh+7,000$30,170→ 116,811 total - Sale
Common Stock
2022-03-15$39.57/sh−375$14,839→ 116,436 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-15−7,000→ 50,723 totalExercise: $4.31Exp: 2027-08-20→ Common Stock (7,000 underlying)
Footnotes (2)
- [F1]This is a scheduled sale from 10B5-1 trading plan.
- [F2]This stock option was granted on 08/21/2017 and is fully vested.